New Liver Cancer Drug To Be Tested at Scripps MD Anderson
Note to Patients: The following news is posted for archival purposes only. Scripps no longer has a formal partnership with MD Anderson Cancer Center. We currently provide comprehensive cancer care through Scripps Cancer Center.
Experimental drug may improve response to immune therapy
Experimental drug may improve response to immune therapy
Darren Sigal, MD, a hematologist and oncologist at Scripps MD Anderson Cancer Center, was recently featured in a news article discussing a new liver cancer drug that the US Food and Drug Administration (FDA) has approved for testing in patients.The new drug is to be tested at Scripps MD Anderson Cancer Center.
Read the article in The San Diego Union-Tribune: Experimental liver cancer drug developed at Scripps Research cleared for testing
Media Contact
- Keith Darce
- 858-678-7121
- darce.keith@scrippshealth.org
- Follow me: @KeithDarce